Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study
European Journal of Neurology2024Vol. 32(1), pp. e16535–e16535
Citations Over TimeTop 10% of 2024 papers
Diego Santos‐García, Lydia López Manzanares, Inés Muro, Pablo Lorenzo‐Barreto, Erik Jesús Huánuco Casas, R. García-Ramos, Tamara Fernández Valle, Carlos Morata‐Martínez, Raquel Baviera‐Muñoz, Irene Martínez‐Torres, María Álvarez‐Sauco, D. Alonso-Modino, Inés Legarda, María Fuensanta Valero‐García, José Andrés Suárez‐Muñoz, Juan Carlos Martínez‐Castrillo, Ana Belén Perona Moratalla, José María Salom, Esther Cubo, Caridad Valero‐Merino, Núria López Ariztegui, Pilar Sánchez Alonso, S. Novo Ponte, Emily Solano González, Raquel Martín García, Raúl Espinosa, Mar Carmona‐Abellán, Cici Feliz, Pedro Ruiz, Teresa Muñoz Ruíz, Beatriz Fernández Rodríguez, Marina Mata
Abstract
LECIG was safe and effective in advanced PD patients.
Related Papers
- → Levodopa‐entacapone‐carbidopa intestinal gel in Parkinson's disease: A randomized crossover study(2016)107 cited
- → Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial(2011)54 cited
- → Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects(2022)3 cited
- → Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules: Comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone(2015)
- → Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules: comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone(2015)